美国和日本胃癌的基因组与临床特征比较:倾向评分匹配队列研究
该回顾性队列研究对比了2010至2019年间在MSK(n=142)和FHU(n=108)接受根治性胃切除术并随访≥5年的胃癌患者的靶向测序数据与临床特征。倾向评分匹配(按年龄、性别、临床T/N分期、肿瘤部位,各58例)后,两国胃癌的基因改变谱和5年总生存率无显著差异(MSK 60% vs FHU 69.4%,P=0.548),但MSK队列微卫星不稳定高(MSI-high)比例更高(22.4% vs 5.2%,P=0.013),且KMT2D突变更常见(18% vs 5%,P<0.05)。结论支持临床试验数据在不同地域间的适用性。
要点
- 匹配后美日胃癌基因组改变和生存无显著差异。
- MSK队列MSI-high比例更高(22.4% vs 5.2%)。
- 腹膜复发MSK更常见(47% vs 34%),但与基因组无关。
核心结论
- 调整临床协变量后,美国与日本胃癌的基因组景观和生存结果相当,支持临床试验数据跨地域适用。
研究设计与样本
- 回顾性队列研究,纳入2010-2019年接受根治性胃切除术且随访≥5年的患者,MSK n=142,FHU n=108,进行靶向测序。
- 倾向评分匹配按年龄、性别、临床T/N分期和肿瘤部位进行,匹配后各58例。
主要发现
- 常见基因改变包括TP53(60%)、ARID1A(17%)、ERBB2(14%)、CCNE1(13%)、KRAS(12%)。
- MSK肿瘤MSI-high比例更高(22.4% vs 5.2%,P=0.013),KMT2D突变更常见(18% vs 5%,P<0.05)。
- 其他基因和通路水平改变在未匹配、微卫星稳定仅限和PSM队列中相似。
- PSM队列5年总生存率相当(MSK 60% vs FHU 69.4%,P=0.548)。
- MSK队列腹膜复发更常见(47% vs 34%),但复发模式与基因组谱无关联。
临床怎么用
- 临床实践中可参考不同地域的胃癌临床试验数据,因基因组和生存结果相似。
- 对于MSI-high和KMT2D突变,应考虑地域差异,MSK队列发生率更高。
- 腹膜复发在MSK队列更常见,需关注复发模式差异。
局限性
- 回顾性研究设计,样本量有限(MSK 142例,FHU 108例),PSM后各58例。
- 仅进行靶向测序,可能遗漏其他基因组改变。
- 随访≥5年,但未报告更长期结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Gastric cancer incidence, risk factors, and survival outcomes differ significantly between Japan and the United States. These disparities have led to the belief that gastric cancer represents biologically distinct diseases across regions. However, direct genomic comparisons of tumours from these populations have not been performed. The aim of this study was to compare the genomic and clinical characteristics of gastric cancers in patients from the US and Japan following curative-intent resection. METHODS: A retrospective cohort study of patients who underwent curative-intent gastrectomy between 2010 and 2019 at Memorial Sloan Kettering (MSK, n = 142) and Fujita Health University (FHU, n = 108), with ≥5 years of follow-up, was conducted. Tumour samples underwent targeted sequencing. Clinical and genomic data were compared between unmatched and propensity score-matched (PSM) cohorts, matched by age, sex, clinical T/N-category, and tumour location (n = 58 each). RESULTS: Commonly altered genes included TP53 (60%), ARID1A (17%), ERBB2 (14%), CCNE1 (13%), and KRAS (12%). MSK tumours showed higher rates of microsatellite instability (MSI-high; 22.4% versus 5.2%, P = 0.013) and KMT2D mutations (18% versus 5%, P < 0.05). Otherwise, gene- and pathway-level alterations were similar across unmatched, microsatellite stable only, and PSM cohorts. Five-year overall survival in PSM cohorts was comparable (MSK 60% versus FHU 69.4%, P = 0.548). Peritoneal recurrence was more common in the MSK cohort (47% versus 34%), but recurrence patterns were not associated with distinct genomic profiles. CONCLUSION: After adjustment for clinical covariates, US and Japanese gastric cancers exhibit comparable genomic landscapes and survival, supporting the relevance of clinical trial data across geographic settings.
引用
- Nakauchi M, Court C, Walch HS, et al. Genomic and clinical parallels between US and Japanese gastric cancers: a propensity score-matched cohort study. Br J Surg. 2025. PMID: 41400038. doi:10.1093/bjs/znaf280
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。